9/14/2026
Psyence BioMed expands U.S. ibogaine research with Texas unit
New subsidiary aims to centralize ibogaine supply and regulatory efforts in the U.S.
Topic archive
mental health
24 stories
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/8/2026
Ibogaine and the bicameral mind book release highlights growing interest
Jonathan Dickinson's new book explores ibogaine's therapeutic potential amid rising U.S. policy focus.
9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/27/2026
Psychedelic medicine gains momentum globally
Israel urged to engage in psychedelic research and development.
8/25/2026
Ibogaine research explores postpartum depression
New framework investigates ibogaine's potential in treating postpartum depression.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/21/2026
Ibogaine research gains momentum for PTSD treatment
Trump administration accelerates psychedelic research for veterans' mental health.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence Biomedical welcomes U.S. support for ibogaine
U.S. backing could accelerate ibogaine research for mental health.
8/19/2026
Trump supports psychedelic drugs for veterans' mental health
Former President Trump advocates for psychedelic treatment to aid veterans.
8/19/2026
Psyence Biomedical stock rises 27% on ibogaine research
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Trump emphasizes ibogaine development, Psyence BioMed reacts
Former President Trump supports ibogaine research, sparking industry response.
8/18/2026
Puerto Rico advances psychedelic therapy research
Governor's order initiates ibogaine, MDMA, and psilocybin study
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.
7/27/2026
Ibogaine treatment provision included in defense bill
New NDAA provision aims to expand ibogaine access for veterans.
7/23/2026
Trump executive order boosts psychedelic therapy research
Order encourages psychedelic research, allocates $50M for state studies.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.
7/19/2026
Psychedelic drugs market sees positive growth signal
Investment interest grows in psychedelics for mental health treatment.
7/17/2026
Ibogaine's long-term brain effects explored
Psychedelics like ibogaine may offer lasting brain changes.
7/16/2026
Texas leaders advocate ibogaine research
Veterans report transformative effects from psychedelic treatment.
7/16/2026
Texas leaders advocate ibogaine research
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Texas leaders advocate for ibogaine research
Veterans share recovery stories, highlighting ibogaine's potential.
7/15/2026
US backs psychedelic therapy research for veterans
Federal support for ibogaine and other psychedelics aims to aid veterans with PTSD.